



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 138051**

**TO: Ben Sackey**  
**Location: 5b31/5c18**  
**Art Unit: 1626**  
**Thursday, November 18, 2004**  
  
**Case Serial Number: 10/612014**

**From: Noble Jarrell**  
**Location: Biotech-Chem Library**  
**Rem 1B71**  
**Phone: 272-2556**  
  
**Noble.jarrell@uspto.gov**

### **Search Notes**

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Ben Sackey Examiner #: 673489 Date: 11/17/04  
 Art Unit: 1626 Phone Number ~~30~~ 82-0704 Serial Number: 10162612014  
 Mail Box and Bldg/Room Location: 5831 Results Format Preferred (circle): PAPER DISK E-MAIL  
5C18

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

*Please search Claim 1 Compound w/ specified (highlighted) variables and elected species.*

\*\*\*\*\*  
**STAFF USE ONLY**


	Type of Search	Vendors and cost where applicable
Searcher: <u>Noble</u>	NA Sequence (#) _____	STN <u>621</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>2</u>	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic <u>✓</u>	Dr.Link _____
Date Completed: _____	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>30</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>60</u>	Other _____	Other (specify) _____

FILE "REGISTRY" ENTERED AT 08:40:08 ON 18 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Crossover limits have been increased. See HELP CROSSOVER for details.

=> d que stat 19  
L7 STR



```

REP G1=(7-20) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS   AT   3
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE  
L9 8 SEA FILE=REGISTRY SSS FUL L7


[illegible]

=> d ide 19 tot'

```

L9  ANSWER 1 OF 8  REGISTRY  COPYRIGHT 2004 ACS on STN
RN  676125-87-4  REGISTRY
CN  Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-[2-
    (nitrooxy)ethoxy]ethoxy]ethyl ester (9CI)  (CA INDEX NAME)
MF  C20 H22 Cl2 N2 O7
SR  CA
LC  STN Files:  CA, CAPLUS, CASREACT
DT.CA  Caplus document type:  Patent
RL.P  Roles from patents:  PREP (Preparation)


```



Search done by Noble Jarrell

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646511-50-4 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate  
FS 3D CONCORD  
MF C20 H23 N O10 S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646510-88-5 REGISTRY  
CN Ethanedioic acid, 2-[(2S)-2-(6-methoxy-2-naphthalenyl)-1-oxopropoxy]ethyl 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]ethyl 3-(nitrooxy)propyl ethane-1,2-dioate  
FS STEREOSEARCH  
MF C21 H23 N O10  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646510-17-0 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
FS STEREOSEARCH  
MF C20 H23 N O10 S

SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 646510-09-0 REGISTRY  
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[[2-(nitrooxy)ethyl]amino]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)-(9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN [N-Methyl-N-[[[N-[2-(nitrooxy)ethyl]carbamoyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 FS STEREOSEARCH  
 MF C21 H25 N3 O8  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 646510-05-6 REGISTRY  
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[3-(nitrooxy)propoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)-(9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN [N-Methyl-N-[[[3-(nitrooxy)propyl]oxy]carbonyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 FS STEREOSEARCH  
 MF C22 H26 N2 O9  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646509-99-1 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[2-(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN [N-Methyl-N-[[[2-(nitrooxy)ethyl]oxy]carbonyl]methyl]carbamoyl]methyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate

FS STEREOSEARCH

MF C21 H24 N2 O9


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); ~~USES~~  
(Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 639067-65-5 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl  
ester, (.alpha.S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C24 H33 N O6


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

=> d que stat 144  
L42 STR



VAR G1=CH2/12  
REP G2=(7-20) A  
NODE ATTRIBUTES:  
NSPEC IS RC AT 1  
DEFAULT MLEVEL IS ATOM  
GGCAT IS UNS AT 3  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 13


STEREO ATTRIBUTES: NONE  
L44 7 SEA FILE=REGISTRY SSS FUL L42

100.0% PROCESSED 1933 ITERATIONS  
SEARCH TIME: 00.00.02

7 ANSWERS

=> d ide 144 tot

L44 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646511-50-4 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate  
FS 3D CONCORD  
MF C20 H23 N O10 S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646510-88-5 REGISTRY  
CN Ethanedioic acid, 2-[(2S)-2-(6-methoxy-2-naphthalenyl)-1-oxopropoxy]ethyl 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]ethyl 3-(nitrooxy)propyl ethane-1,2-dioate  
FS STEREOSEARCH  
MF C21 H23 N O10  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES

Search done by Noble Jarrell

(Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646510-17-0 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
FS STEREOSEARCH  
MF C20 H23 N O10 S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646510-09-0 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[[2-(nitrooxy)ethyl]amino]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN [N-Methyl-N-[[N-[2-(nitrooxy)ethyl]carbonyl]methyl]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
FS STEREOSEARCH  
MF C21 H25 N3 O8  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646510-05-6 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[3-(nitrooxy)propoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN [N-Methyl-N-[[[3-(nitrooxy)propyl]oxy]carbonyl]methyl]carbamoyl]methyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate  
FS STEREOSEARCH  
MF C22 H26 N2 O9  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 646509-99-1 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[2-(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN [N-Methyl-N-[[[2-(nitrooxy)ethyl]oxy]carbonyl]methyl]carbamoyl]methyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate  
FS STEREOSEARCH  
MF C21 H24 N2 O9  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)

Absolute stereochemistry.




## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 639067-65-5 REGISTRY  
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl  
ester, (.alpha.S)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C24 H33 N O6  
SR CA  
LC STN Files: CA, CAPLUS  
DT.CA CAPLUS document type: Patent  
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 08:04:54 ON 18 NOV 2004)

FILE 'REGISTRY' ENTERED AT 08:04:59 ON 18 NOV 2004

L1 STR  
L2 0 L1  
L3 STR L1  
L4 0 L3  
L5 STR L3  
L6 0 L5  
L7 STR L5  
L8 0 L7  
L9 8 L7 FULL

FILE 'HCAPLUS' ENTERED AT 08:23:29 ON 18 NOV 2004  
L10 1 US20040024057/PN

FILE 'REGISTRY' ENTERED AT 08:23:41 ON 18 NOV 2004

FILE 'HCAPLUS' ENTERED AT 08:23:42 ON 18 NOV 2004  
L11 TRA L10 1- RN : 265 TERMS

FILE 'REGISTRY' ENTERED AT 08:23:42 ON 18 NOV 2004  
L12 265 SEA L11  
L13 6 L9 AND L12

FILE 'HCAPLUS' ENTERED AT 08:24:37 ON 18 NOV 2004  
L14 3 L9

FILE 'HCAOLD' ENTERED AT 08:24:43 ON 18 NOV 2004  
L15 0 L9

FILE 'HCAPLUS' ENTERED AT 08:24:47 ON 18 NOV 2004  
L16 E EARL R/AU  
55 E3-4, E8-10  
E EZAWA M/AU  
L17 15 E3-5  
E FANG X/AU  
L18 190 E3-18  
E FANG XINQIN/AU

Search done by Noble Jarrell

L19 25 E3  
 E GARVEY D/AU  
 L20 127 E3,E8,E10,E12  
 E GASTON R/AU  
 L21 26 E3-4,E11-14  
 E KNANAPURE S/AU  
 E KHANAPURE S/AU  
 L22 88 E4-7  
 E LETTS L/AU  
 L23 90 E4-5  
 E LETTS G/AU  
 L24 17 E3,E7-8  
 E LIN C/AU  
 L25 364 E3,E14  
 E LIN CHIA/AU  
 L26 14 E3,E17  
 E RANATUNGE R/AU  
 L27 10 E4-5  
 E RICHARDSON S/AU  
 L28 54 E3,E15  
 E RICHARDSON STEWART/AU  
 L29 38 E3-4  
 E SCHROEDER J/AU  
 L30 284 E3,E6-7  
 E SCHROEDER JO/AU  
 L31 34 E49,E51-52  
 E STEVENSON C/AU  
 L32 22 E3-4  
 E STEVENSON CHERI/AU  
 L33 2 E4  
 E WEY S/AU  
 L34 13 E3-4,E12  
 L35 93 (NITROMED OR NITRO (1A) MED?)/CS,PA  
 L36 1 L14 AND L16-35  
 L37 2 L14 NOT L36  
  
 FILE 'REGISTRY' ENTERED AT 08:31:07 ON 18 NOV 2004  
 L38 1 C21H24N2O9 AND L9  
  
 FILE 'HCAPLUS' ENTERED AT 08:31:38 ON 18 NOV 2004  
 L39 1 L38  
 L40 1 L39 AND L16-35  
 L41 1 L36 OR L40  
  
 FILE 'REGISTRY' ENTERED AT 08:32:11 ON 18 NOV 2004  
 L42 STR  
 L43 0 L42  
 L44 7 L42 FULL  
 SAVE TEMP L44 SAC014F1/A  
  
 FILE 'HCAPLUS' ENTERED AT 08:37:05 ON 18 NOV 2004  
 L45 2 L44  
  
 FILE 'HCAOLD' ENTERED AT 08:37:12 ON 18 NOV 2004  
 L46 0 L44  
  
 FILE 'HCAPLUS' ENTERED AT 08:37:19 ON 18 NOV 2004  
 L47 1 L45 AND L16-35  
 L48 1 L45 NOT L47  
  
 FILE 'STNGUIDE' ENTERED AT 08:37:35 ON 18 NOV 2004  
  
 FILE 'HCAPLUS' ENTERED AT 08:38:40 ON 18 NOV 2004  
 L49 1 L41 OR L47

=> b hcap

FILE 'HCAPLUS' ENTERED AT 08:40:54 ON 18 NOV 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

Search done by Noble Jarrell

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2004 VOL 141 ISS 21  
FILE LAST UPDATED: 17 Nov 2004 (20041117/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

--> d all fhitr 149 tot


L49 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:41217 HCAPLUS  
DN 140:111135  
ED Entered STN: 18 Jan 2004  
TI Preparation of nitrosated nonsteroidal antiinflammatory compounds  
IN Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin  
; Garvey, David S.; Gaston, Ricky D.; Khanapure,  
Subhash P.; Letts, Gordon L.; Lin, Chia-En;  
Ranatunge, Ramani R.; Richardson, Stewart K.;  
Schroeder, Joseph D.; Stevenson, Cheri A.; Wey,  
Shiow-Jyi  
PA Nitromed, Inc., USA  
SO PCT Int. Appl., 145 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K  
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)  
Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004648	A2	20040115	WO 2003-US21026	20030703
WO 2004004648	A3	20041028		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004024057	A1	20040205	US 2003-612014	20030703
PRAI US 2002-393111P	P	20020703		
US 2002-397979P	P	20020724		
US 2002-418353P	P	20021016		
US 2003-449798P	P	20030226		
US 2003-456182P	P	20030321		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004004648	ICM	A61K
OS MARPAT 140:111135		
GI		



AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S, I] are prepared For instance, naproxen is coupled to

Search done by Noble Jarrell

2,2'-thiodiethanol (CH<sub>2</sub>Cl<sub>2</sub>, DMAP, EDCI) and treated with Ac<sub>2</sub>O/HNO<sub>3</sub> at 0.degree. to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.

- ST nitrosated nonsteroidal antiinflammatory pain prepn
- IT Intestine, disease  
(Crohn's; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Antihistamines  
(H<sub>2</sub>, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Pancreas, neoplasm  
(Zollinger-Ellison syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Carcinoma  
(adenocarcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Nose, disease  
(allergic rhinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Thromboxanes  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antagonists, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Infection  
(bacterial; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Skin, neoplasm  
(basal cell carcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Leukemia  
(basophilic; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Bronchi, disease  
(bronchitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Lip  
Mouth  
(cancer; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Nervous system, disease  
(central; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Uterus, neoplasm  
(cervix; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Intestine, neoplasm  
(colon; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 5-HT agonists  
Analgesics  
Antihistamines  
Antitumor agents  
Decongestants  
Diuretics  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Opioids  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Steroids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Intestine, disease  
(constipation; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Mental disorder  
(dementia, multi-infarct; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mental disorder  
(dementia, vascular; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Animal tissue  
(deterioration; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Tendon  
(disease, tendinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Urogenital tract  
(disease; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Immunity  
Sexual behavior  
(disorder; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Reticuloendothelial system  
(dysfunction, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Neoplasm  
(epithelial; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Fibrosis  
(from radiation therapy, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Stomach, disease  
(gastritis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Digestive tract, disease  
(gastroesophageal reflux; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Stomach, disease  
(gastroparesis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease  
(inflammatory; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Helicobacter pylori  
Platelet aggregation inhibitors  
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Reperfusion  
(injury; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease  
(irritable bowel syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Prostanoid receptors  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(isoprostane, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Leukotriene receptors  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(leukotriene B4, antagonist, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mast cell  
(neoplasm, mastocytoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Thiols (organic), biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nitrosated derivs., combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Anti-inflammatory agents  
(nonsteroidal, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Parturition  
(premature; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Alzheimer's disease  
Amnesia  
Angiogenesis  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Antiarthritics

Antiasthmatics  
 Antimicrobial agents  
 Autoimmune disease  
 Bladder, neoplasm  
 Brain, neoplasm  
 Carcinoma  
 Cardiovascular system, disease  
 Digestive tract, disease  
 Digestive tract, neoplasm  
 Dyspepsia  
 Esophagus, neoplasm  
 Inflammation  
 Liver, neoplasm  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Neoplasm  
 Neutrophil  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Respiratory distress syndrome  
 Skin, neoplasm  
 Stomach, neoplasm  
 Wound healing  
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)  
 IT Transport proteins  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (proton pump, inhibitor, combination pharmaceutical; preparation of  
 naproxen-derived nitrosated antiinflammatory compds.)  
 IT Kidney, neoplasm  
 (renal cell carcinoma; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)  
 IT Mental disorder  
 (senile psychosis; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)  
 IT Shock (circulatory collapse)  
 (septic; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)  
 IT Intestine, disease  
 (short bowel syndrome; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)  
 IT Intestine  
 (small, cancer; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)  
 IT Carcinoma  
 (squamous cell; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)  
 IT Digestive tract, disease  
 (ulcer, peptic; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)  
 IT Intestine, disease  
 (ulcerative colitis; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)  
 IT 50-78-2D, Aspirin, nitrosated derivs. 53-86-1D, Indomethacin, nitrosated  
 derivs. 56-85-9, Glutamine, biological studies 56-87-1, Lysine,  
 biological studies 61-68-7D, Mefenamic acid, nitrosated derivs.  
 65-45-2D, Salicylamide, nitrosated derivs. 70-26-8, Ornithine 74-79-3,  
 L-Arginine, biological studies 74-79-3D, L-Arginine, nitrosated derivs.  
 89-57-6D, Mesalamine, nitrosated derivs. 156-86-5, L-Homoarginine  
 156-86-5D, L-Homoarginine, nitrosated derivs. 372-75-8, Citrulline  
 490-79-9D, Gentisic acid, nitrosated derivs. 530-78-9D, Flufenamic acid,  
 nitrosated derivs. 552-94-3D, Salsalate, nitrosated derivs. 644-62-2D,  
 Meclofenamic acid, nitrosated derivs. 959-10-4D, Xenbucin, nitrosated  
 derivs. 1553-60-2D, Ibufenac, nitrosated derivs. 3583-64-0D,  
 Bumadizon, nitrosated derivs. 4394-00-7D, Niflumic acid, nitrosated  
 derivs. 5104-49-4D, Flurbiprofen, nitrosated derivs. 5728-52-9D,  
 Felbinac, nitrosated derivs. 13710-19-5D, Tolfenamic acid, nitrosated  
 derivs. 13799-03-6D, Protizinic acid, nitrosated derivs. 13993-65-2D,  
 Metiazinic acid, nitrosated derivs. 15307-86-5D, Diclofenac, nitrosated  
 derivs. 15687-27-1D, Ibuprofen, nitrosated derivs. 17969-20-9D,  
 Fenclozic acid, nitrosated derivs. 18046-21-4D, Fentiazac, nitrosated  
 derivs. 20168-99-4D, Cinmetacin, nitrosated derivs. 20187-55-7D,  
 Bendazac, nitrosated derivs. 21256-18-8D, Oxaprozin, nitrosated derivs.  
 22071-15-4D, Ketoprofen, nitrosated derivs. 22204-53-1D, Naproxen,  
 nitrosated derivs. 22494-42-4D, Diflunisal, nitrosated derivs.  
 23049-93-6D, Enfenamic acid, nitrosated derivs. 26171-23-3D, Tolmetin,

nitrosated derivs. 27470-51-5D, Suxibuzone, nitrosated derivs.  
 29679-58-1D, Fenoprofen, nitrosated derivs. 31793-07-4D, Pirofen,  
 nitrosated derivs. 31842-01-0D, Indoprofen, nitrosated derivs.  
 32808-51-8D, Bucloxic acid, nitrosated derivs. 33005-95-7D, Tiaprofenic  
 acid, nitrosated derivs. 33369-31-2D, Zomepirac, nitrosated derivs.  
 34148-01-1D, Clidanac, nitrosated derivs. 36330-85-5D, Fenbufen,  
 nitrosated derivs. 38194-50-2D, Sulindac, nitrosated derivs.  
 38677-85-9D, Flunixin, nitrosated derivs. 39718-89-3D, Alminoprofen,  
 nitrosated derivs. 40828-46-4D, Suprofen, nitrosated derivs.  
 41340-25-4D, Etodolac, nitrosated derivs. 42779-82-8D, Clopirac,  
 nitrosated derivs. 50270-33-2D, Isofezolac, nitrosated derivs.  
 51234-28-7D, Benoxaprofen, nitrosated derivs. 51579-82-9D, Amfenac,  
 nitrosated derivs. 52549-17-4D, Pranoprofen, nitrosated derivs.  
 53164-05-9D, Acemetacin, nitrosated derivs. 53597-27-6D, Fendosal,  
 nitrosated derivs. 53716-49-7D, Carprofen, nitrosated derivs.  
 53808-88-1D, Lonazolac, nitrosated derivs. 55453-87-7D, Isoxepac,  
 nitrosated derivs. 55837-18-8D, Butibufen, nitrosated derivs.  
 55843-86-2D, Mioprofen, nitrosated derivs. 56187-89-4D, Ximoprofen,  
 nitrosated derivs. 66934-18-7D, Flunoxaprofen, nitrosated derivs.  
 68767-14-6D, Loxoprofen, nitrosated derivs. 74103-06-3D, Ketorolac,  
 nitrosated derivs. 74711-43-6D, Zaltoprofen, nitrosated derivs.  
 78967-07-4D, Mofezolac, nitrosated derivs. 89796-99-6D, Aceclofenac,  
 nitrosated derivs. 91714-94-2D, Bromfenac, nitrosated derivs.  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination pharmaceutical; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)

- IT 9002-04-4, Thrombin 9028-35-7, 3-Hydroxy-3-methylglutaryl coenzyme A  
 reductase 39391-18-9, Cyclooxygenase 80619-02-9, 5-Lipoxygenase  
 90119-07-6, Leukotriene A4 hydrolase 125978-95-2, Nitric oxide synthase  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (inhibitor, combination pharmaceutical; preparation of naproxen-derived  
 nitrosated antiinflammatory compds.)
- IT 9000-96-8, Arginase  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibitor, combination pharmaceutical; preparation of naproxen-derived  
 nitrosated antiinflammatory compds.)
- IT 10102-43-9, Nitric oxide, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 183195-09-7P, [N-[2-(Nitrooxy)ethyl]carbamoyl]methyl 2-[[2-(6-  
 dichlorophenyl)amino]phenyl]acetate 646509-36-6P, 2-[[2-  
 (Nitrooxy)ethyl]thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-38-8P, 2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-39-9P 646509-41-3P, [2-[[2-  
 (Nitrooxy)ethyl](4-nitrophenyl)amino]ethyl (2S)-2-[6-methoxy-2-  
 naphthyl]propanoate 646509-43-5P, (2R)-2,3-Bis(nitrooxy)propyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-45-7P 646509-47-9P  
 646509-52-6P 646509-55-9P, [5-[(Nitrooxy)methyl]-1,3-dioxan-5-yl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-59-3P,  
 2,2-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-63-9P, 3-[[[4-(Nitrooxymethyl)phenyl]carbonyl]oxy]-2-oxopropyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-67-3P 646509-71-9P,  
 2-Nitro-3-(nitrooxy)-2-(nitrooxymethyl)propyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-75-3P, 2-[[N-[2-(Nitrooxy)ethyl]carbamoyl]oxy  
 ]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-79-7P,  
 3-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-84-4P, 4-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-88-8P, [N-Methyl-N-[2-  
 (nitrooxy)ethyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-94-6P, [N-Ethyl-N-[2-(nitrooxy)ethyl]carbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-98-0P,  
 2-[4-(Nitrooxymethyl)piperidin-1-yl]-2-oxoethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-99-1P, [N-Methyl-N-[[[2-  
 (nitrooxy)ethyl]oxy]carbonyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-05-6P, [N-Methyl-N-[[[3-  
 (nitrooxy)propyl]oxy]carbonyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-09-0P, [N-Methyl-N-[N-[2-  
 (nitrooxy)ethyl]carbamoyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-12-5P, [[[2-(Nitrooxy)ethyl]oxy]carbonyl]meth  
 yl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-15-8P,  
 [N-[3-(Nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-17-0P, [[[2-[[2-  
 (Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-23-8P, [[[(1S,5S,2R,6R)-6-(Nitrooxy)-4,8-  
 dioxabicyclo[3.3.0]octan-2-yl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-

naphthyl)propanoate 646510-27-2P, (2S)-2,3-Bis(nitrooxy)propyl  
 (2S)-2-(6-methoxy-5-nitro-2-naphthyl)propanoate 646510-30-7P,  
 (2S)-2-Hydroxy-3-(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646510-37-4P, (2S)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-39-6P, (2R)-2-Hydroxy-3-(nitrooxy)propyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-41-0P,  
 (2S)-2-(6-Methoxy-2-naphthyl)-N-[[N-(2-(nitrooxy)ethyl)carbamoyl]methoxy]p  
 ropanamide 646510-48-7P, 3-[2-[4-(Nitrooxymethyl)phenyl]acetoxy]-2-  
 oxopropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-52-3P,  
 2-[4-[2-(Nitrooxy)ethyl]piperidin-1-yl]-2-oxoethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-57-8P, 4-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]ph  
 enyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-60-3P,  
 2-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-62-5P, [N-Methyl-N-[3-  
 (nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646510-67-0P, (2S)-2-(6-Methoxy-2-naphthyl)-N-[2-[4-  
 [(nitrooxy)methyl]piperidin-1-yl]-2-oxoethoxy]propanamide 646510-69-2P,  
 3-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-72-7P 646510-79-4P, 3-[[[2-(6-Methoxy-2-  
 naphthyl)propanoyl]oxy]-2-methyl-2-[(nitrooxy)methyl]propyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-83-0P,  
 2-[4-[2-(Nitrooxy)ethoxy]phenoxy]ethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-88-5P, 2-[[[2-(6-Methoxy-2-  
 naphthyl)propanoyl]oxy]ethyl 3-(nitrooxy)propyl ethane-1,2-dioate  
 646510-93-2P, N-[[[2-(6-Methoxy-2-naphthyl)propanoyl]amino]-4-  
 (nitrooxy)butanamide 646511-00-4P, 4-[[[2-(6-Methoxy-2-  
 naphthyl)propanoyl]oxy] (2S,3S)-2,3-bis(nitrooxy)butyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-02-6P,  
 [(2S,3S)-2,3-Bis(nitrooxy)-4-hydroxybutyl] (2S)-2-[6-(methyloxy)-2-  
 naphthyl]propanoate 646511-07-1P, 2-[[[3-[(Nitrooxy)methyl]phenyl]carbon  
 yl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-14-0P,  
 (2R)-2-(Nitrooxy)-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646511-18-4P 646511-22-0P, [(1S,2S,5S,6R)-6-  
 (Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-yl] 2-[1-[(4-  
 chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate  
 646511-23-1P, [(1S,2S,5S,6R)-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-  
 yl] 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646511-25-3P,  
 2-[[[4-Methylphenyl]sulfonyl]2-(nitrooxy)ethyl]amino]ethyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-28-6P 646511-30-0P,  
 (2R)-2,3-Bis(nitrooxy)propyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-  
 methylindol-3-yl]acetate 646511-32-2P, (2S)-2,3-Bis(nitrooxy)propyl  
 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate  
 646511-34-4P, (2S)-2,3-Bis(nitrooxy)propyl 2-[2-[(2,6-  
 dichlorophenyl)amino]phenyl]acetate 646511-36-6P, (2R)-2,3-  
 Bis(nitrooxy)propyl 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate  
 646511-37-7P, (2S)-2-(6-Methoxy-2-naphthyl)-1-[[4-  
 (nitrooxy)butyl]thio]propan-1-one 646511-41-3P, [N-Methyl-N-[2-  
 (nitrooxy)ethyl]carbamoyl]methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-  
 2-methylindol-3-yl]acetate 646511-43-5P, [N-[2-  
 (Nitrooxy)ethyl]carbamoyl]methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-  
 2-methylindol-3-yl]acetate 646511-47-9P, [[2-  
 (Nitrooxy)ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate  
 646511-48-0P, [N-[3-(Nitrooxy)propyl]carbamoyl]methyl 2-(6-methoxy-2-  
 naphthyl)propanoate 646511-50-4P, [[2-[[2-  
 (Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-  
 naphthyl)propanoate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 53-86-1, Indomethacin 77-49-6, 2-Nitro-2-methyl-1,3-propanediol  
 77-85-0, 1,1,1-Tris(hydroxymethyl)ethane 96-26-4, 1,3-Dihydroxyacetone  
 99-06-9, 3-Hydroxybenzoic acid, reactions 99-96-7, 4-Hydroxybenzoic  
 acid, reactions 103-76-4, 1-Piperazineethanol 104-38-1 109-83-1,  
 Methyl[2-(hydroxy)ethyl]amine 109-94-4, Ethyl formate 110-73-6  
 111-42-2, Diethanolamine, reactions 111-48-8, 2,2'-Thiodiethanol  
 126-11-4, 2-Hydroxymethyl-2-nitro-1,3-propanediol 141-43-5,  
 2-Hydroxyethylamine, reactions 156-87-6, 3-Amino-1-propanol 350-46-9,  
 4-Fluoronitrobenzene 504-63-2, 1,3-Propanediol 524-38-9,  
 N-Hydroxyphthalimide 540-51-2, 2-Bromoethanol 622-26-4,  
 2-(Piperidin-4-yl)ethanol 627-18-9, 3-Bromo-1-propanol 2319-57-5,  
 L-Threitol 3084-40-0, Diethyl (hydroxymethyl)phosphonate 5292-43-3,  
 tert-Butyl bromoacetate 6228-25-7, 1,3-Dioxane-5,5-dimethanol  
 6232-88-8, .alpha.-Bromo-p-toluic acid 6457-49-4, (Piperidin-4-  
 yl)methanol 7146-67-0, N,N-Bis(2-hydroxyethyl)-p-toluenesulfonamide  
 13737-36-5, [4-(Bromomethyl)phenyl]acetic acid 14347-78-5,

((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 14970-83-3,  
 4-Mercapto-1-butanol 15307-86-5, Diclofenac 16051-77-7, Isosorbide  
 5-mononitrate 18162-48-6, tert-Butyldimethylsilyl chloride 22204-53-1  
 22323-82-6, ((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 26159-34-2,  
 (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid sodium salt 26690-80-2,  
 tert-Butyl N-(2-hydroxyethyl)carbamate 31719-77-4, 3-  
 (Chloromethyl)benzoic acid 42865-19-0, 2-Bromoethyl isocyanate  
 56552-80-8, (R)-(+)-3-Benzoyloxy-1,2-propanediol 58479-61-1,  
 tert-Butylchlorodiphenylsilane 86940-98-9, ((4S)-2,2,4-Trimethyl-1,3-  
 dioxolan-4-yl)methanol 136088-69-2 646509-51-5, [4-Nitro-1-(nitrooxy)-  
 2-[(nitrooxy)methyl]butan-2-yl]amine 646510-25-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)  
 IT 4665-58-1P, [2-(Nitrooxy)ethyl]ammonium nitrate 18226-17-0P,  
 2-[(2-Hydroxyethyl)(4-nitrophenyl)amino]ethanol 38483-29-3P  
 42055-15-2P, 3-(Methylamino)propan-1-ol 49807-74-1P,  
 N-(3-Hydroxypropyl)carboxamide 53164-05-9P, 2-[2-[1-[(4-  
 Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetyloxy]acetic acid  
 54224-25-8P 56834-02-7P, tert-Butyl 2-aminoxyacetate 57561-39-4P  
 65141-52-8P, [3-(Nitrooxy)propyl]amine nitrate 75302-98-6P,  
 (tert-Butoxycarbonyl)methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-  
 methylindol-3-yl]acetate 87426-50-4P, 2-Hydroxyethyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 97699-68-8P,  
 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]acetic acid 100502-66-7P,  
 3-(Nitrooxy)propan-1-ol 104963-92-0P 105566-73-2P, 2-Aminoethyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate hydrochloride 136404-13-2P  
 139272-68-7P, (tert-Butoxycarbonyl)methyl 2-[2-[(2,6-  
 dichlorophenyl)amino]phenyl]acetate 145459-16-1P, Methyl[2-  
 (nitrooxy)ethyl]ammonium nitrate 154504-21-9P, (2S)-2,3-  
 Bis(nitrooxy)propan-1-ol 161469-42-7P, 1-[[[(4S)-2,2-Dimethyl-1,3-  
 dioxolan-4-yl)methoxy]-2,2-dimethyl-1,1-diphenyl-1-silapropane  
 161469-43-8P, (2S)-3-[(2,2-Dimethyl-1,1-diphenyl-1-silapropyl)oxy]propane-  
 1,2-diol 163385-71-5P, 2-(Nitrooxy)ethyl 4-hydroxybenzoate  
 163385-76-0P, 2-(Nitrooxy)ethyl 2-hydroxybenzoate 163385-79-3P,  
 2-(Nitrooxy)ethyl 3-hydroxybenzoate 258278-55-6P, 4-  
 (Nitrooxymethyl)benzoic acid 364057-16-9P 364057-29-4P,  
 2-[N-(tert-Butoxycarbonyl)-N-methylamino]ethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 364057-30-7P, 2-(Methylamino)ethyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 382601-32-3P,  
 (2R)-2,3-Bis(nitrooxy)propan-1-ol 385369-72-2P, 2-[(2-  
 Hydroxyethyl)sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-37-7P, 2-[(2-Hydroxyethyl)thio]ethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-40-2P 646509-42-4P, 2-[(2-Hydroxyethyl)(4-  
 nitrophenyl)amino]ethyl 2-(6-methoxy-2-naphthyl)propanoate 646509-44-6P  
 646509-46-8P, Phosphonomethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-57-1P, [5-(Hydroxymethyl)-1,3-dioxan-5-yl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-61-7P,  
 3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-65-1P, 3-Hydroxy-2-oxopropyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-69-5P 646509-73-1P,  
 3-Hydroxy-2-(hydroxymethyl)-2-nitropropyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646509-77-5P, 2-[N-(2-Bromoethyl)carbamoyl]oxy]ethy  
 l (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-82-2P, 3-Hydroxyphenyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-86-6P, 4-Hydroxyphenyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-90-2P,  
 (tert-Butyloxycarbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-97-9P, Ethyl[2-(nitrooxy)ethyl]ammonium nitrate 646510-00-1P,  
 [N-[(tert-Butoxycarbonyl)methyl]-N-methylcarbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-01-2P 646510-03-4P,  
 [N-[[[(2-Hydroxyethyl)oxy]carbonyl]methyl]-N-methylcarbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-07-8P,  
 [N-[[[(3-Hydroxypropyl)oxy]carbonyl]methyl]-N-methylcarbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-13-6P,  
 [[[(2-Hydroxyethyl)oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-19-2P, [[[(2-Hydroxyethylthio)ethyl]oxy]car  
 bonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-21-6P,  
 [[[(2-Hydroxyethyl)sulfonyl]ethyl]oxy]carbonyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-32-9P,  
 ((4R)-2,2,4-Trimethyl-1,3-dioxolan-4-yl)methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-35-2P, [(2R)-2,3-Dihydroxy-2-methylpropyl]  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-44-3P, tert-Butyl  
 2-[[[(2S)-2-(6-methoxy-2-naphthyl)propanoyl]amino]oxy]acetate  
 646510-46-5P, 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]oxy]acetic  
 acid 646510-50-1P, 2-[4-(Nitrooxymethyl)phenyl]acetic acid  
 646510-54-5P 646510-65-8P, Methyl[3-(nitrooxy)propyl]amine  
 646510-74-9P 646510-77-2P 646510-81-8P, 2-[[[(2S)-2-(6-Methoxy-2-

naphthyl)propanoyl]oxy)methyl]-3-hydroxy-2-methylpropyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-85-2P,  
2-[4-(2-Hydroxyethoxy)phenoxy]ethyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-95-4P 646510-98-7P, N-[[[(2S)-2-(6-Methoxy-2-  
naphthyl)propanoyl]amino]-4-hydroxybutanamide 646511-03-7P,  
(2S,3S)-1,4-Bis[(1,1,2,2-tetramethyl-1-silapropyl)oxy]butane-2,3-diol  
646511-04-8P, (2S,3S)-1,4-Bis[(1,1,2,2-tetramethyl-1-silapropyl)oxy]-2,3-  
bis(nitrooxy)butane 646511-06-0P, (2S,3S)-2,3-Bis(nitrooxy)butane-1,4-  
diol 646511-09-3P, 3-[(Nitrooxy)methyl]benzoic acid 646511-11-7P,  
2-[(tert-Butoxycarbonyl)amino]ethyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646511-15-1P, (2R)-2-Hydroxy-3-(phenylmethoxy)propyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-27-5P,  
2-[(2-Hydroxyethyl)[(4-methylphenyl)sulfonyl]amino]ethyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-39-9P,  
(2S)-1-[(4-Hydroxybutyl)thio]-2-(6-methoxy-2-naphthyl)propan-1-one  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 51209-75-7, S-Nitroso-cysteine 56577-02-7, S-Nitroso-N-acetylcysteine  
57564-91-7, S-Nitroso-glutathione 79032-48-7, S-Nitroso-N-  
acetylpenicillamine 122130-63-6, S-Nitroso-captopril 139427-42-2,  
S-Nitroso-homocysteine 162758-33-0, S-Nitroso-cysteinylglycine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)


IT 646509-99-1P, [N-Methyl-N-[[[2-(nitrooxy)ethyl]oxy]carbonyl]methyl  
l]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

RN 646509-99-1 HCAPLUS

CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-[methyl[2-[2-  
(nitrooxy)ethoxy]-2-oxoethyl]amino]-2-oxoethyl ester, (.alpha.S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 137 tot

L37 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:267282 HCAPLUS

DN 140:287165

ED Entered STN: 01 Apr 2004

TI Manufacturing process for NO-donating compounds such as NO-donating  
diclofenac

IN Andersson, Johan; Belli, Aldo; Cannata, Vincenzo; Hedberg, Martin;

Palmgren, Andreas; Schuldei, Sigrid; Stroem, Marika; Villa, Marco

PA Astrazeneca UK Limited, UK; Astrazeneca AB

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C201-00

ICS C07C309-63; A61K031-216; A61P029-00; C07C211-55; C07C067-03;  
C07C303-28

CC 25-8 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026808	A1	20040401	WO 2003-SE1465	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

Search done by Noble Jarrell

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,  
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
 GW, ML, MR, NE, SN, TD, TG

PRAI SE 2002-2801 A 20020920  
 SE 2003-1476 A 20030520

## CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2004026808 ICM C07C201-00  
 ICS C07C309-63; A61K031-216; A61P029-00; C07C211-55;  
 C07C067-03; C07C303-28

OS CASREACT 140:287165; MARPAT 140:287165

AB NO-Donating compds. MLnAmCO2XONOp [M = residue of an NSAID, COX-1  
 inhibitor or COX-2 inhibitor; L = O, S, CO2, (un)substituted CONH, NH, CO,  
 CH2, CH2CO, CH2CONH, CH2CO2; A = (un)substituted alkylene; X = carbon  
 linker; m, n = 0-3; p = 1, 2] are prepared by treating MLnAmCO2H with HOXOH,  
 treating MLnAmCO2XOH with RSO2Cl [R = alkyl, (un)substituted Ph, CH2Ph,  
 halogen, CF3, C4F9], and treating MLnAmCO2XO3SR with nitrate. A  
 substantially crystalline form of 2-[2-(nitrooxy)ethoxy]ethyl  
 {2-[(2,6-dichlorophenyl)amino]phenyl}acetate is reported.

ST nitrooxyalkyl ester NSAID COX inhibitor prepn nitric oxide donor

IT 10102-43-9, Nitrogen oxide (NO), biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (manufacturing process for NO-donating compds. such as NO-donating  
 diclofenac)

IT 174454-43-4P  
 RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic  
 preparation); PREP (Preparation)  
 (manufacturing process for NO-donating compds. such as NO-donating  
 diclofenac)

IT 108914-03-OP 120339-21-1P 354145-58-7P 409067-32-9P 676125-81-8P  
 676125-85-2P 676125-90-9P 676125-93-2P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic  
 preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (manufacturing process for NO-donating compds. such as NO-donating  
 diclofenac)

IT 156661-01-7P 639067-51-9P 676125-87-4P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (manufacturing process for NO-donating compds. such as NO-donating  
 diclofenac)

IT 110-63-4, 1,4-Butanediol, reactions 111-46-6, Diethylene glycol,  
 reactions 504-63-2, 1,3-Propanediol 15307-79-6, Diclofenac sodium  
 22161-81-5, (S)-Ketoprofen  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (manufacturing process for NO-donating compds. such as NO-donating  
 diclofenac)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) Gianfranco, C; J Chem Soc Perkin Trans 1987, V1, P2637  
 (2) Gianfranco, C; Tetrahedron Letters 1985, V41(7), P1385  
 (3) Gianfranco, C; Tetrahedron Letters 1985, V26(28), P3369  
 (4) Kiyoshi, K; Chem Pharm Bull 1990, V38(8), P2092  
 (5) Nicox Limited; WO 9509831 A1 1995 HCAPLUS  
 (6) Nicox Limited; WO 9530641 A1 1995 HCAPLUS  
 (7) Ru, J; Synthesis 1994, P471  
 (8) Union de Espanola de Explosivos S A; ES 2073995 A1 1995 HCAPLUS

IT 676125-87-4P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (manufacturing process for NO-donating compds. such as NO-donating  
 diclofenac)

RN 676125-87-4 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-[2-  
 (nitrooxy)ethoxy]ethoxy]ethyl ester (9CI) (CA INDEX NAME)




FAN.CNT 1

PRAI IT 2002-MI1392

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004000273	ICM	A61K009-107
	ICS	A61K031-216; A61K031-235; A61K031-407; A61K031-426; A61K031-44; A61K031-4164; A61K031-4709

GI



# I

ST oral pharmaceutical lig nitrate ester NSAID

IT Glycerides, biological studies

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)  
 (C8-10, ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Quaternary ammonium compounds, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (alkylbenzylidimethyl, chlorides; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Drug delivery systems  
 (capsules; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Castor oil  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Anti-inflammatory agents  
 (nonsteroidal, nitrate esters; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Drug bioavailability  
 Surfactants  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Alcohols, biological studies  
 Bentonite, biological studies  
 Clays, biological studies  
 Glycerides, biological studies  
 Kaolin, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT Drug delivery systems  
 (tablets; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT 56-81-5, Glycerol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 67-68-5, DmsO, biological studies 68-12-2, Dmf, biological studies 71-23-8, 1-Propanol, biological studies 71-36-3, 1-Butanol, biological studies 78-83-1, Isobutyl alcohol, biological studies 107-21-1, Ethylene glycol, biological studies 111-90-0 127-19-5, Dimethylacetamide 151-21-3, Sodium lauryl sulfate, biological studies 558-43-0, Isobutylene glycol 577-11-7, Dioctyl sodium sulfosuccinate 593-29-3, Potassium stearate 616-45-5, 2-Pyrrolidone 822-16-2, Sodium stearate 1309-42-8, Magnesium hydroxide 7631-86-9, Silica, biological studies 8044-71-1, Cetrinide 9002-92-0, Polyoxyethylene lauryl ether 9004-34-6, Cellulose, biological studies 9005-25-8, Starch, biological studies 9016-45-9, Polyoxyethylene nonylphenyl ether 12619-70-4, Cyclodextrin 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 21645-51-2, Aluminum hydroxide, biological studies 25265-75-2, Butylene glycol 63799-56-4, Labrafac 74791-03-0  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)


IT 50-53-3, Chlorpromazine, biological studies 54-11-5, Nicotine 55-63-0, Nitroglycerin 77-38-3, Chlorphenoxamine 99-66-1, Valproic acid 104-31-4, Benzonatate 113-92-8, Chlorpheniramine maleate 461-78-9, Chlorphentermine 637-07-0, Clofibrate 156661-01-7 156970-83-1 158836-71-6 163133-43-5 164790-48-1 171781-26-3 174454-43-4 174454-49-0 175033-36-0 204633-00-1 301669-93-2 302543-79-9 311336-57-9 311336-59-1 311336-64-8 311336-66-0 352464-58-5 352464-62-1 497818-52-7 569371-19-3 639067-51-9 639067-52-0 639067-53-1 639067-54-2 639067-55-3 639067-56-4 639067-57-5 639067-58-6 639067-59-7 639067-60-0 639067-61-1 639067-62-2 639067-63-3 639067-64-4 639067-65-5 639067-66-6 639067-67-7 639067-68-8 639067-69-9 639067-70-2 639067-71-3 639067-72-4 639067-73-5 639067-75-7  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE  
 (1) Astrazeneca Ab; WO 0166087 A 2001 HCAPLUS  
 (2) Astrazeneca Ab; WO 0166088 A 2001 HCAPLUS

(3) Nicox Sa; WO 0061537 A 2000 HCAPLUS  
 IT 639067-65-5  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having  
 improved bioavailability)  
 RN 639067-65-5 HCAPLUS  
 CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl  
 ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 148 tot

L48 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2004:2666 HCAPLUS  
 DN 140:65191  
 ED Entered STN: 02 Jan 2004  
 TI Oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having  
 improved bioavailability  
 IN Del Soldato, Piero; Santus, Giancarlo; Macelloni, Cristina  
 PA Nicox S.A., Fr.  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-107  
 ICS A61K031-216; A61K031-235; A61K031-407; A61K031-426; A61K031-44;  
 A61K031-4164; A61K031-4709  
 CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004000273	A1	20031231	WO 2003-EP6496	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRAI IT 2002-MI1392

A 20020625

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004000273	ICM	A61K009-107
	ICS	A61K031-216; A61K031-235; A61K031-407; A61K031-426; A61K031-44; A61K031-4164; A61K031-4709

GI



- AB The present invention relates to new pharmaceutical compns. for the administration of liquid drugs in solid oral forms, said compns. comprising one or more active ingredients, one or more surface-active agents and optionally a co-surfactant and/or an absorption enhancer absorbed on a solid inert carrier. An emulsion was prepared containing I 100, Cremophor EL 50, Phospholipon 80H 50, Aerosil 200 100, and Explotab 100 g.
- ST oral pharmaceutical liq nitrate ester NSAID
- IT Glycerides, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C8-10, ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Quaternary ammonium compounds, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkylbenzyltrimethyl, chlorides; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Drug delivery systems  
 (capsules; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Castor oil  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (ethoxylated; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Anti-inflammatory agents  
 (nonsteroidal, nitrate esters; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Drug bioavailability  
 Surfactants  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Alcohols, biological studies  
 Bentonite, biological studies  
 Clays, biological studies  
 Glycerides, biological studies  
 Kaolin, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT Drug delivery systems  
 (tablets; oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
- IT 56-81-5, Glycerol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 67-68-5, Dmsol, biological studies 68-12-2, Dmf, biological studies 71-23-8, 1-Propanol, biological studies 71-36-3, 1-Butanol, biological studies 78-83-1, Isobutyl alcohol, biological studies 107-21-1, Ethylene glycol, biological studies 111-90-0 127-19-5, Dimethylacetamide 151-21-3, Sodium lauryl sulfate, biological studies 558-43-0, Isobutylene glycol 577-11-7, Dioctyl sodium sulfosuccinate 593-29-3, Potassium stearate 616-45-5, 2-Pyrrolidone 822-16-2, Sodium stearate 1309-42-8, Magnesium hydroxide 7631-86-9, Silica, biological studies 8044-71-1, Cetrimide 9002-92-0, Polyoxyethylene lauryl ether 9004-34-6, Cellulose, biological studies 9005-25-8, Starch, biological studies 9016-45-9, Polyoxyethylene nonylphenyl ether 12619-70-4, Cyclodextrin 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 21645-51-2, Aluminum hydroxide, biological studies 25265-75-2, Butylene glycol 63799-56-4, Labrafac 74791-03-0  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

IT 50-53-3, Chlorpromazine, biological studies 54-11-5, Nicotine 55-63-0, Nitroglycerin 77-38-3, Chlorphenoxamine 99-66-1, Valproic acid 104-31-4, Benzonatate 113-92-8, Chlorpheniramine maleate 461-78-9, Chlorphentermine 637-07-0, Clofibrate 156661-01-7 156970-83-1 158836-71-6 163133-43-5 164790-48-1 171781-26-3 174454-43-4 174454-49-0 175033-36-0 204633-00-1 301669-93-2 302543-79-9 311336-57-9 311336-59-1 311336-64-8 311336-66-0 352464-58-5 352464-62-1 497818-52-7 569371-19-3 639067-51-9 639067-52-0 639067-53-1 639067-54-2 639067-55-3 639067-56-4 639067-57-5 639067-58-6 639067-59-7 639067-60-0 639067-61-1 639067-62-2 639067-63-3 639067-64-4 639067-65-5 639067-66-6 639067-67-7 639067-68-8 639067-69-9 639067-70-2 639067-71-3 639067-72-4 639067-73-5 639067-75-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Astrazeneca Ab; WO 0166087 A 2001 HCAPLUS

(2) Astrazeneca Ab; WO 0166088 A 2001 HCAPLUS

(3) Nicox Sa; WO 0061537 A 2000 HCAPLUS

IT 639067-65-5


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)

RN 639067-65-5 HCAPLUS

CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 10-(nitrooxy)decyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; b home

FILE 'HOME' ENTERED AT 08:41:35 ON 18 NOV 2004

=&gt;

=> d his

(FILE 'HOME' ENTERED AT 07:12:39 ON 18 NOV 2004)

L1 FILE 'HCAPLUS' ENTERED AT 07:12:49 ON 18 NOV 2004  
1 US20040024057/PN

FILE 'REGISTRY' ENTERED AT 07:13:16 ON 18 NOV 2004

L2 FILE 'HCAPLUS' ENTERED AT 07:13:18 ON 18 NOV 2004  
TRA L1 1- RN : 265 TERMS

L3 FILE 'REGISTRY' ENTERED AT 07:13:19 ON 18 NOV 2004  
265 SEA L2

L4 FILE 'WPIX' ENTERED AT 07:13:23 ON 18 NOV 2004  
1 US20040024057/PN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 07:13:44 ON 18 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2004 VOL 141 ISS 21  
FILE LAST UPDATED: 17 Nov 2004 (20041117/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 11

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:41217 HCAPLUS  
DN 140:111135  
ED Entered STN: 18 Jan 2004  
TI Preparation of nitrosated nonsteroidal antiinflammatory compounds  
IN Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey, David S.; Gaston, Ricky D.; Khanapure, Subhash P.; Letts, Gordon L.; Lin, Chia-En; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.; Stevenson, Cheri A.; Wey, Shiow-Jyi  
PA Nitromed, Inc., USA  
SO PCT Int. Appl., 145 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K  
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)  
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004648	A2	20040115	WO 2003-US21026	20030703
	WO 2004004648	A3	20041028		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

Search done by Noble Jarrell

US 2004024057	A1	20040205	US 2003-612014	20030703 <--
PRAI US 2002-393111P	P	20020703		
US 2002-397979P	P	20020724		
US 2002-418353P	P	20021016		
US 2003-449798P	P	20030226		
US 2003-456182P	P	20030321		


## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004004648	ICM	A61K
---------------	-----	------

OS MARPAT 140:111135

GI



- AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prepared For instance, naproxen is coupled to 2,2'-thiodiethanol (CH<sub>2</sub>Cl<sub>2</sub>, DMAP, EDCI) and treated with Ac<sub>2</sub>O/HNO<sub>3</sub> at 0.degree. to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.
- ST nitrosated nonsteroidal antiinflammatory pain prepn
- IT Intestine, disease  
(Crohn's; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Antihistamines  
(H<sub>2</sub>, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Pancreas, neoplasm  
(Zollinger-Ellison syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Carcinoma  
(adenocarcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Nose, disease  
(allergic rhinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Thromboxanes  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antagonists, inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Infection  
(bacterial; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Skin, neoplasm  
(basal cell carcinoma; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Leukemia  
(basophilic; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Bronchi, disease  
(bronchitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Lip  
Mouth  
(cancer; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Nervous system, disease  
(central; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT Uterus, neoplasm

(cervix; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, neoplasm  
(colon; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 5-HT agonists  
Analgesics  
Antihistamines  
Antitumor agents  
Decongestants  
Diuretics  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Opioids  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Steroids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease  
(constipation; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mental disorder  
(dementia, multi-infarct; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Mental disorder  
(dementia, vascular; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Animal tissue  
(deterioration; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Tendon  
(disease, tendinitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Urogenital tract  
(disease; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Immunity  
Sexual behavior  
(disorder; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Reticuloendothelial system  
(dysfunction, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Neoplasm  
(epithelial; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Fibrosis  
(from radiation therapy, treatment; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Stomach, disease  
(gastritis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Digestive tract, disease  
(gastroesophageal reflux; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Stomach, disease  
(gastroparesis; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease  
(inflammatory; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Helicobacter pylori  
Platelet aggregation inhibitors  
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Reperfusion  
(injury; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Intestine, disease  
(irritable bowel syndrome; preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Prostanoid receptors  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)  
 (isoprostane, inhibitor, combination pharmaceutical; preparation of  
 naproxen-derived nitrosated antiinflammatory compds.)

IT Leukotriene receptors  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (leukotriene B4, antagonist, combination pharmaceutical; preparation of  
 naproxen-derived nitrosated antiinflammatory compds.)

IT Mast cell  
 (neoplasm, mastocytoma; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)

IT Thiols (organic), biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (nitrosated derivs., combination pharmaceutical; preparation of  
 naproxen-derived nitrosated antiinflammatory compds.)

IT Anti-inflammatory agents  
 (nonsteroidal, combination pharmaceutical; preparation of naproxen-derived  
 nitrosated antiinflammatory compds.)

IT Parturition  
 (premature; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)

IT Alzheimer's disease  
 Amnesia  
 Angiogenesis  
 Anti-Alzheimer's agents  
 Anti-inflammatory agents  
 Antiarthritics  
 Antiasthmatics  
 Antimicrobial agents  
 Autoimmune disease  
 Bladder, neoplasm  
 Brain, neoplasm  
 Carcinoma  
 Cardiovascular system, disease  
 Digestive tract, disease  
 Digestive tract, neoplasm  
 Dyspepsia  
 Esophagus, neoplasm  
 Inflammation  
 Liver, neoplasm  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Neoplasm  
 Neutrophil  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Respiratory distress syndrome  
 Skin, neoplasm  
 Stomach, neoplasm  
 Wound healing  
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT Transport proteins  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (proton pump, inhibitor, combination pharmaceutical; preparation of  
 naproxen-derived nitrosated antiinflammatory compds.)

IT Kidney, neoplasm  
 (renal cell carcinoma; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)

IT Mental disorder  
 (senile psychosis; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)

IT Shock (circulatory collapse)  
 (septic; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)

IT Intestine, disease  
 (short bowel syndrome; preparation of naproxen-derived nitrosated  
 antiinflammatory compds.)

IT Intestine  
 (small, cancer; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)

IT Carcinoma  
 (squamous cell; preparation of naproxen-derived nitrosated antiinflammatory  
 compds.)

IT Digestive tract, disease  
 (ulcer, peptic; preparation of naproxen-derived nitrosated antiinflammatory

- compds.)
- IT Intestine, disease  
(ulcerative colitis; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 50-78-2D, Aspirin, nitrosated derivs. 53-86-1D, Indomethacin, nitrosated derivs. 56-85-9, Glutamine, biological studies 56-87-1, Lysine, biological studies 61-68-7D, Mefenamic acid, nitrosated derivs. 65-45-2D, Salicylamide, nitrosated derivs. 70-26-8, Ornithine 74-79-3, L-Arginine, biological studies 74-79-3D, L-Arginine, nitrosated derivs. 89-57-6D, Mesalamine, nitrosated derivs. 156-86-5, L-Homoarginine 156-86-5D, L-Homoarginine, nitrosated derivs. 372-75-8, Citrulline 490-79-9D, Gentisic acid, nitrosated derivs. 530-78-9D, Flufenamic acid, nitrosated derivs. 552-94-3D, Salsalate, nitrosated derivs. 644-62-2D, Meclofenamic acid, nitrosated derivs. 959-10-4D, Xenbucin, nitrosated derivs. 1553-60-2D, Ibufenac, nitrosated derivs. 3583-64-0D, Bumadizon, nitrosated derivs. 4394-00-7D, Niflumic acid, nitrosated derivs. 5104-49-4D, Flurbiprofen, nitrosated derivs. 5728-52-9D, Felbinac, nitrosated derivs. 13710-19-5D, Tolfenamic acid, nitrosated derivs. 13799-03-6D, Protizinic acid, nitrosated derivs. 13993-65-2D, Metiazinic acid, nitrosated derivs. 15307-86-5D, Diclofenac, nitrosated derivs. 15687-27-1D, Ibuprofen, nitrosated derivs. 17969-20-9D, Fenclozic acid, nitrosated derivs. 18046-21-4D, Fentiazac, nitrosated derivs. 20168-99-4D, Cinmetacin, nitrosated derivs. 20187-55-7D, Bendazac, nitrosated derivs. 21256-18-8D, Oxaprozin, nitrosated derivs. 22071-15-4D, Ketoprofen, nitrosated derivs. 22204-53-1D, Naproxen, nitrosated derivs. 22494-42-4D, Diflunisal, nitrosated derivs. 23049-93-6D, Efenamic acid, nitrosated derivs. 26171-23-3D, Tolmetin, nitrosated derivs. 27470-51-5D, Suxibuzone, nitrosated derivs. 29679-58-1D, Fenoprofen, nitrosated derivs. 31793-07-4D, Pirprofen, nitrosated derivs. 31842-01-0D, Indoprofen, nitrosated derivs. 32808-51-8D, Bucloxic acid, nitrosated derivs. 33005-95-7D, Tiaprofenic acid, nitrosated derivs. 33369-31-2D, Zomepirac, nitrosated derivs. 34148-01-1D, Clidanac, nitrosated derivs. 36330-85-5D, Fenbufen, nitrosated derivs. 38194-50-2D, Sulindac, nitrosated derivs. 38677-85-9D, Flunixin, nitrosated derivs. 39718-89-3D, Alminoprofen, nitrosated derivs. 40828-46-4D, Suprofen, nitrosated derivs. 41340-25-4D, Etodolac, nitrosated derivs. 42779-82-8D, Clopirac, nitrosated derivs. 50270-33-2D, Isofezolac, nitrosated derivs. 51234-28-7D, Benoxaprofen, nitrosated derivs. 51579-82-9D, Amfenac, nitrosated derivs. 52549-17-4D, Pranoprofen, nitrosated derivs. 53164-05-9D, Acemetacin, nitrosated derivs. 53597-27-6D, Fendosal, nitrosated derivs. 53716-49-7D, Carprofen, nitrosated derivs. 53808-88-1D, Lonazolac, nitrosated derivs. 55453-87-7D, Isoxepac, nitrosated derivs. 55837-18-8D, Butibufen, nitrosated derivs. 55843-86-2D, Mioprofen, nitrosated derivs. 56187-89-4D, Ximoprofen, nitrosated derivs. 66934-18-7D, Flunoxaprofen, nitrosated derivs. 68767-14-6D, Loxoprofen, nitrosated derivs. 74103-06-3D, Ketorolac, nitrosated derivs. 74711-43-6D, Zaltoprofen, nitrosated derivs. 78967-07-4D, Mofezolac, nitrosated derivs. 89796-99-6D, Aceclofenac, nitrosated derivs. 91714-94-2D, Bromfenac, nitrosated derivs.  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 9002-04-4, Thrombin 9028-35-7, 3-Hydroxy-3-methylglutaryl coenzyme A reductase 39391-18-9, Cyclooxygenase 80619-02-9, 5-Lipoxygenase 90119-07-6, Leukotriene A4 hydrolase 125978-95-2, Nitric oxide synthase  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 9000-96-8, Arginase  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhibitor, combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 10102-43-9, Nitric oxide, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of naproxen-derived nitrosated antiinflammatory compds.)
- IT 183195-09-7P, [N-[2-(Nitrooxy)ethyl]carbamoyl]methyl 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646509-36-6P, 2-[2-(Nitrooxy)ethyl]thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-38-8P, 2-[2-(Nitrooxy)ethyl]sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-39-9P 646509-41-3P, [2-[2-(Nitrooxy)ethyl](4-nitrophenyl)amino]ethyl (2S)-2-[6-methoxy-2-naphthyl]propanoate 646509-43-5P, (2R)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-45-7P 646509-47-9P 646509-52-6P 646509-55-9P, [5-[(Nitrooxy)methyl]-1,3-dioxan-5-yl]methyl

(2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-59-3P,  
2,2-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
646509-63-9P, 3-[[[4-(Nitrooxymethyl)phenyl]carbonyl]oxy]-2-oxopropyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-67-3P 646509-71-9P,  
2-Nitro-3-(nitrooxy)-2-(nitrooxymethyl)propyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646509-75-3P, 2-[[N-[2-(Nitrooxy)ethyl]carbamoyl]oxy  
ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-79-7P,  
3-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
646509-84-4P, 4-[2-(Nitrooxy)ethoxy]phenyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646509-88-8P, [N-Methyl-N-[2-  
(nitrooxy)ethyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
646509-94-6P, [N-Ethyl-N-[2-(nitrooxy)ethyl]carbamoyl]methyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-98-0P,  
2-[4-(Nitrooxymethyl)piperidin-1-yl]-2-oxoethyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646509-99-1P, [N-Methyl-N-[[[2-  
(nitrooxy)ethyl]oxy]carbonyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-05-6P, [N-Methyl-N-[[[3-  
(nitrooxy)propyl]oxy]carbonyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-09-0P, [N-Methyl-N-[N-[2-  
(nitrooxy)ethyl]carbamoyl]methyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-12-5P, [[2-(Nitrooxy)ethyl]oxy]carbonyl]meth  
yl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-15-8P,  
[N-[3-(Nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-17-0P, [[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethy  
l]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
646510-23-8P, [[[(1S,5S,2R,6R)-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-  
2-yl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
646510-27-2P, (2S)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-5-nitro-2-  
naphthyl)propanoate 646510-30-7P, (2S)-2-Hydroxy-3-(nitrooxy)propyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-37-4P,  
(2S)-2,3-Bis(nitrooxy)propyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
646510-39-6P, (2R)-2-Hydroxy-3-(nitrooxy)propyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-41-0P, (2S)-2-(6-Methoxy-2-naphthyl)-N-[N-[2-  
(nitrooxy)ethyl]carbamoyl]methoxy]propanamide 646510-48-7P,  
3-[2-[4-(Nitrooxymethyl)phenyl]acetoxy]-2-oxopropyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-52-3P, 2-[4-[2-(Nitrooxy)ethyl]piperidin-1-  
yl]-2-oxoethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-57-8P,  
4-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-60-3P, 2-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]ph  
enyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-62-5P,  
[N-Methyl-N-[3-(nitrooxy)propyl]carbamoyl]methyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-67-0P, (2S)-2-(6-Methoxy-2-naphthyl)-N-[2-[4-  
(nitrooxy)methyl]piperidin-1-yl]-2-oxoethoxy]propanamide 646510-69-2P,  
3-[[[2-(Nitrooxy)ethyl]oxy]carbonyl]phenyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-72-7P 646510-79-4P, 3-[[[2S)-2-(6-Methoxy-2-  
naphthyl)propanoyl]oxy]-2-methyl-2-[(nitrooxy)methyl]propyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-83-0P,  
2-[4-[2-(Nitrooxy)ethoxy]phenoxy]ethyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646510-88-5P, 2-[[[2S)-2-(6-Methoxy-2-  
naphthyl)propanoyl]oxy]ethyl 3-(nitrooxy)propyl ethane-1,2-dioate  
646510-93-2P, N-[[[2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]-4-  
(nitrooxy)butanamide 646511-00-4P, 4-[[[2S)-2-(6-Methoxy-2-  
naphthyl)propanoyl]oxy] (2S,3S)-2,3-bis(nitrooxy)butyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-02-6P,  
[[2S,3S)-2,3-Bis(nitrooxy)-4-hydroxybutyl] (2S)-2-[6-(methyloxy)-2-  
naphthyl]propanoate 646511-07-1P, 2-[[[3-[(Nitrooxy)methyl]phenyl]carbon  
yl]amino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-14-0P,  
(2R)-2-(Nitrooxy)-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy-2-  
naphthyl)propanoate 646511-18-4P 646511-22-0P, [(1S,2S,5S,6R)-6-  
(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-yl] 2-[1-[(4-  
chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate  
646511-23-1P, [(1S,2S,5S,6R)-6-(Nitrooxy)-4,8-dioxabicyclo[3.3.0]octan-2-  
yl] 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 646511-25-3P,  
2-[[[4-Methylphenyl]sulfonyl]2-(nitrooxy)ethyl]amino]ethyl  
(2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-28-6P 646511-30-0P,  
(2R)-2,3-Bis(nitrooxy)propyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-  
methylindol-3-yl]acetate 646511-32-2P, (2S)-2,3-Bis(nitrooxy)propyl  
2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate  
646511-34-4P, (2S)-2,3-Bis(nitrooxy)propyl 2-[2-[(2,6-  
dichlorophenyl)amino]phenyl]acetate 646511-36-6P, (2R)-2,3-  
Bis(nitrooxy)propyl 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate  
646511-37-7P, (2S)-2-(6-Methoxy-2-naphthyl)-1-[[4-  
(nitrooxy)butyl]thio]propan-1-one 646511-41-3P, [N-Methyl-N-[2-  
(nitrooxy)ethyl]carbamoyl]methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-  
2-methylindol-3-yl]acetate 646511-43-5P, [N-[2-  
(Nitrooxy)ethyl]carbamoyl]methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-

2-methylindol-3-yl]acetate 646511-47-9P, [[2-(Nitrooxy)ethyl]oxy]carbonylmethyl 2-(6-methoxy-2-naphthyl)propanoate 646511-48-0P, [N-[3-(Nitrooxy)propyl]carbamoyl]methyl 2-(6-methoxy-2-naphthyl)propanoate 646511-50-4P, [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonylmethyl 2-(6-methoxy-2-naphthyl)propanoate  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 53-86-1, Indomethacin 77-49-6, 2-Nitro-2-methyl-1,3-propanediol 77-85-0, 1,1,1-Tris(hydroxymethyl)ethane 96-26-4, 1,3-Dihydroxyacetone 99-06-9, 3-Hydroxybenzoic acid, reactions 99-96-7, 4-Hydroxybenzoic acid, reactions 103-76-4, 1-Piperazineethanol 104-38-1 109-83-1, Methyl[2-(hydroxy)ethyl]amine 109-94-4, Ethyl formate 110-73-6 111-42-2, Diethanolamine, reactions 111-48-8, 2,2'-Thiodiethanol 126-11-4, 2-Hydroxymethyl-2-nitro-1,3-propanediol 141-43-5, 2-Hydroxyethylamine, reactions 156-87-6, 3-Amino-1-propanol 350-46-9, 4-Fluoronitrobenzene 504-63-2, 1,3-Propanediol 524-38-9, N-Hydroxyphthalimide 540-51-2, 2-Bromoethanol 622-26-4, 2-(Piperidin-4-yl)ethanol 627-18-9, 3-Bromo-1-propanol 2319-57-5, L-Threitol 3084-40-0, Diethyl (hydroxymethyl)phosphonate 5292-43-3, tert-Butyl bromoacetate 6228-25-7, 1,3-Dioxane-5,5-dimethanol 6232-88-8, .alpha.-Bromo-p-toluic acid 6457-49-4, (Piperidin-4-yl)methanol 7146-67-0, N,N-Bis(2-hydroxyethyl)-p-toluenesulfonamide 13737-36-5, [4-(Bromomethyl)phenyl]acetic acid 14347-78-5, ((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 14970-83-3, 4-Mercapto-1-butanol 15307-86-5, Diclofenac 16051-77-7, Isosorbide 5-mononitrate 18162-48-6, tert-Butyldimethylsilyl chloride 22204-53-1 22323-82-6, ((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methanol 26159-34-2, (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid sodium salt 26690-80-2, tert-Butyl N-(2-hydroxyethyl)carbamate 31719-77-4, 3-(Chloromethyl)benzoic acid 42865-19-0, 2-Bromoethyl isocyanate 56552-80-8, (R)-(+)-3-Benzoyloxy-1,2-propanediol 58479-61-1, tert-Butylchlorodiphenylsilane 86940-98-9, ((4S)-2,2,4-Trimethyl-1,3-dioxolan-4-yl)methanol 136088-69-2 646509-51-5, [4-Nitro-1-(nitrooxy)-2-[(nitrooxy)methyl]butan-2-yl]amine 646510-25-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)

IT 4665-58-1P, [2-(Nitrooxy)ethyl]ammonium nitrate 18226-17-0P, 2-[(2-Hydroxyethyl)(4-nitrophenyl)amino]ethanol 38483-29-3P 42055-15-2P, 3-(Methylamino)propan-1-ol 49807-74-1P, N-(3-Hydroxypropyl)carboxamide 53164-05-9P, 2-[2-[1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetyloxy]acetic acid 54224-25-8P 56834-02-7P, tert-Butyl 2-aminoxyacetate 57561-39-4P 65141-52-8P, [3-(Nitrooxy)propyl]amine nitrate 75302-98-6P, (tert-Butoxycarbonyl)methyl 2-[1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl]acetate 87426-50-4P, 2-Hydroxyethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 97699-68-8P, 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]oxy]acetic acid 100502-66-7P, 3-(Nitrooxy)propan-1-ol 104963-92-0P 105566-73-2P, 2-Aminoethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate hydrochloride 136404-13-2P 139272-68-7P, (tert-Butoxycarbonyl)methyl 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate 145459-16-1P, Methyl[2-(nitrooxy)ethyl]ammonium nitrate 154504-21-9P, (2S)-2,3-Bis(nitrooxy)propan-1-ol 161469-42-7P, 1-[[[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methoxy]-2,2-dimethyl-1,1-diphenyl-1-silapropene 161469-43-8P, (2S)-3-[(2,2-Dimethyl-1,1-diphenyl-1-silapropyl)oxy]propane-1,2-diol 163385-71-5P, 2-(Nitrooxy)ethyl 4-hydroxybenzoate 163385-76-0P, 2-(Nitrooxy)ethyl 2-hydroxybenzoate 163385-79-3P, 2-(Nitrooxy)ethyl 3-hydroxybenzoate 258278-55-6P, 4-(Nitrooxymethyl)benzoic acid 364057-16-9P 364057-29-4P, 2-[N-(tert-Butoxycarbonyl)-N-methylamino]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 364057-30-7P, 2-(Methylamino)ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 382601-32-3P, (2R)-2,3-Bis(nitrooxy)propan-1-ol 385369-72-2P, 2-[(2-Hydroxyethyl)sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-37-7P, 2-[(2-Hydroxyethyl)thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-40-2P 646509-42-4P, 2-[(2-Hydroxyethyl)(4-nitrophenyl)amino]ethyl 2-(6-methoxy-2-naphthyl)propanoate 646509-44-6P 646509-46-8P, Phosphonomethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-57-1P, [5-(Hydroxymethyl)-1,3-dioxan-5-yl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-61-7P, 3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-65-1P, 3-Hydroxy-2-oxopropyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-69-5P 646509-73-1P, 3-Hydroxy-2-(hydroxymethyl)-2-nitropropyl (2S)-2-(6-methoxy-2-

naphthyl)propanoate 646509-77-5P, 2-[[N-(2-Bromoethyl)carbamoyl]oxy]ethyl  
 1 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-82-2P, 3-Hydroxyphenyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-86-6P, 4-Hydroxyphenyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-90-2P,  
 (tert-Butyloxycarbonyl)methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate  
 646509-97-9P, Ethyl 2-(nitrooxy)ethyl ammonium nitrate 646510-00-1P,  
 [N-[(tert-Butoxycarbonyl)methyl]-N-methylcarbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-01-2P 646510-03-4P,  
 [N-[[[(2-Hydroxyethyl)oxy]carbonyl]methyl]-N-methylcarbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-07-8P,  
 [N-[[[(3-Hydroxypropyl)oxy]carbonyl]methyl]-N-methylcarbamoyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-13-6P,  
 [[(2-Hydroxyethyl)oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-19-2P, [[2-(2-Hydroxyethylthio)ethyl]oxy]car-  
 bonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-21-6P,  
 [[2-[(2-Hydroxyethyl)sulfonyl]ethyl]oxy]carbonyl]methyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-32-9P,  
 ((4R)-2,2,4-Trimethyl-1,3-dioxolan-4-yl)methyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-35-2P, [(2R)-2,3-Dihydroxy-2-methylpropyl]  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-44-3P, tert-Butyl  
 2-[[[(2S)-2-(6-methoxy-2-naphthyl)propanoyl]amino]oxy]acetate  
 646510-46-5P, 2-[[[(2S)-2-(6-Methoxy-2-naphthyl)propanoyl]amino]oxy]acetic  
 acid 646510-50-1P, 2-[4-(Nitrooxymethyl)phenyl]acetic acid  
 646510-54-5P 646510-65-8P, Methyl 3-(nitrooxy)propylamine  
 646510-74-9P 646510-77-2P 646510-81-8P, 2-[[[(2S)-2-(6-Methoxy-2-  
 naphthyl)propanoyl]oxy]methyl]-3-hydroxy-2-methylpropyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-85-2P,  
 2-[4-(2-Hydroxyethoxy)phenoxy]ethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646510-95-4P 646510-98-7P, N-[[[(2S)-2-(6-Methoxy-2-  
 naphthyl)propanoyl]amino]-4-hydroxybutanamide 646511-03-7P,  
 (2S,3S)-1,4-Bis[(1,1,2,2-tetramethyl-1-silapropyl)oxy]butane-2,3-diol  
 646511-04-8P, (2S,3S)-1,4-Bis[(1,1,2,2-tetramethyl-1-silapropyl)oxy]-2,3-  
 bis(nitrooxy)butane 646511-06-0P, (2S,3S)-2,3-Bis(nitrooxy)butane-1,4-  
 diol 646511-09-3P, 3-[(Nitrooxy)methyl]benzoic acid 646511-11-7P,  
 2-[(tert-Butoxycarbonyl)amino]ethyl (2S)-2-(6-methoxy-2-  
 naphthyl)propanoate 646511-15-1P, (2R)-2-Hydroxy-3-(phenylmethoxy)propyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-27-5P,  
 2-[(2-Hydroxyethyl)[(4-methylphenyl)sulfonyl]amino]ethyl  
 (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-39-9P,  
 (2S)-1-[(4-Hydroxybutyl)thio]-2-(6-methoxy-2-naphthyl)propan-1-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of naproxen-derived nitrosated antiinflammatory compds.)  
 IT 51209-75-7, S-Nitroso-cysteine 56577-02-7, S-Nitroso-N-acetylcysteine  
 57564-91-7, S-Nitroso-glutathione 79032-48-7, S-Nitroso-N-  
 acetylpenicillamine 122130-63-6, S-Nitroso-captopril 139427-42-2,  
 S-Nitroso-homocysteine 162758-33-0, S-Nitroso-cysteinylglycine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of naproxen-derived nitrosated antiinflammatory compds.)

=> b wpix

FILE 'WPIX' ENTERED AT 07:13:50 ON 18 NOV 2004  
 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE LAST UPDATED: 17 NOV 2004 <20041117/UP>  
 MOST RECENT DERWENT UPDATE: 200474 <200474/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
 FIRST VIEW - FILE WPIFV.  
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF

Search done by Noble Jarrell

## HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT &lt;&lt;&lt;

>>> SMILES and ISOSMILES strings are no longer available as  
Derwent Chemistry Resource display fields <<<

=> d all 14

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN  
AN 2004-191044 [18] WPIX  
DNC C2004-075275  
TI New nitrosated nonsteroidal compounds are cyclooxygenase inhibitors useful  
to treat or reduce e.g. inflammation, pain or fever, gastrointestinal  
disorders, inflammatory diseases and gastrointestinal, renal and/or  
respiratory toxicity.  
DC B05  
IN EARL, R A; EZAWA, M; FANG, X; GARVEY, D S; GASTON, R D; KHANAPURE, S P;  
LETTS, L G; LIN, C; RANATUNGA, R R; RICHARDSON, S K; SCHROEDER, J D;  
STEVENSON, C A; WEY, S; LETTS, G L; RANATUNGE, R R  
PA (NITR-N) NITROMED INC  
CYC 102  
PI WO 2004004648 A2 20040115 (200418)\* EN 145 A61K000-00  
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS  
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT  
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA  
ZM ZW  
US 2004024057 A1 20040205 (200418) A61K031-21 <--  
AU 2003247792 A1 20040123 (200459) A61K000-00  
ADT WO 2004004648 A2 WO 2003-US21026 20030703; US 2004024057 A1 Provisional US  
2002-393111P 20020703, Provisional US 2002-397979P 20020724, Provisional  
US 2002-418353P 20021016, Provisional US 2003-449798P 20030226,  
Provisional US 2003-456182P 20030321, US 2003-612014 20030703; AU  
2003247792 A1 AU 2003-247792 20030703  
FDT AU 2003247792 A1 Based on WO 2004004648  
PRAI US 2003-456182P 20030321; US 2002-393111P 20020703;  
US 2002-397979P 20020724; US 2002-418353P 20021016;  
US 2003-449798P 20030226; US 2003-612014 20030703  
IC ICM A61K000-00; A61K031-21  
ICS C07C002-00  
AB WO2004004648 A UPAB: 20040316  
NOVELTY - Nitrosated nonsteroidal compounds (A) and their salts are new.  
DETAILED DESCRIPTION - Nitrosated nonsteroidal compounds (A) of  
formula Rn-C(Rm)-C(O)-X (I) and RkC(O)-X' (II) and their salts are new.  
Rm = H or lower alkyl;  
Rn = e.g. 4-(thiophen-2-ylcarbonyl)phenyl, 4-(phenylcarbonyl)phenyl,  
4-(1-oxo-isoquinolin-2-yl)phenyl, 5-(4-methylphenylcarbonyl)-N-  
methylpyrrol-2-yl, 4-phenyl-3-fluorophenyl, 5-(phenylcarbonyl)thien-2-yl,  
4-phenoxyphenyl, 6-(methoxy)naphthalen-2-yl or 4,5-diphenyloxazol-2-yl;  
X = e.g. Y-(CR4C4')p-T-(CR4R4')p-ONO2, Y-(CR4R4')q-V-(CR4R4')o-Q'-  
(CR4R4')o-(CH2)-ONO2 or Y-(CR4R4')q-(T)o-(W)q-(CR4R4')o-(CH2)-ONO2;  
R4, R4' = H, lower alkyl, OH, CH2OH, ONO2, NO2 or CH2ONO2;  
CR4 + R4' = cycloalkyl or heterocyclic ring;  
V = C(O)-T, T-C(O), T-C(O)-T or T-C(O)-C(O)-T;  
W = covalent bond or a carbonyl;  
T = O, (S(O)o)o or NRj;  
Rj = H, an alkyl, an aryl, a heterocyclic ring, an alkylcarbonyl, an  
alkylaryl, an alkylsulfinyl, an alkylsulfonyl, an arylsulfinyl, an  
arylsulfonyl, a sulfonamido, a N-alkylsulfonamido, a N,N-  
diarylsulfonamido, a N-arylsulfonamido, a N-alkyl-N-arylsulfonamido, a  
carboxamido or a hydroxyl;  
p = 1-6;  
q = 1-3;  
o = 0-2;  
Y = O or (S);  
B = phenyl or (CH2)o;  
Q' = cycloalkyl group, a heterocyclic ring or an aryl;  
Z = (=O), (=N-OR5), (=N-NR5R'5) or (=CR5R'5);  
M, M' = O- H3N+ (CR4R'4)q-CH2ONO2 or T-(CR4R'4)o-CH2ONO2;  
R5, R5' = H, OH, an alkyl, an aryl, an alkylsulfonyl, an  
arylsulfonyl, a carboxylic ester, an alkylcarbonyl, an arylcarbonyl, a  
carboxamido, an alkoxyalkyl, an alkoxyaryl, a cycloalkyl or heterocyclic  
ring;  
Rk = 2-(2,6-dichloro-3-methylphenylamino)phenyl,  
2-(2,3-dimethylphenylamino)phenyl, 3-(2,4-difluorophenyl)-6-hydroxyphenyl,

Search done by Noble Jarrell

2-hydroxyphenyl, 2-(1-oxoethoxy)phenyl, 2-(2-hydroxyphenylcarbonyloxy)phenyl, 2-(3-(3-trifluoromethylphenylamino)phenyl, 2-(3-trifluoromethylphenylamino)pyridin-3-yl, 2,5-dihydroxyphenyl, 5-amino-2-hydroxyphenyl, 2-(2-phenylethylamino)phenyl, 2-(2-methyl-3-trifluoromethylphenylamino)pyridin-3-yl, 2-(2-hydroxyphenylcarbonyloxy)phenyl, 2-(3-chloro-2-methylphenylamino)phenyl or a group of formula (iii)-(vii);

X' = X or

With provisos.

NB: Full definitions are given in the DEFINITIONS (Full Definitions) section.

INDEPENDENT CLAIMS are also included for

- (1) a composition (B) comprising (I) and a carrier ; and
- (2) a kit comprising (I) .

ACTIVITY - Antiinflammatory; Analgesic; Antipyretic;

Gastrointestinal-Gen.; Laxative; Antiulcer; Tranquillizer; Hemostatic; Antibacterial; Cytostatic; Vulnerary; Cardiovascular-Gen.; Vasotropic; Antiangiogenic; Antiarthritic; Asthmatic; Tocolytic; Immunosuppressive; Dermatological; CNS-Gen.; Antiallergic; Antimicrobial; Virucide; Uropathic; Endocrine-Gen.; Nootropic; Neuroprotective; Ophthalmological; Nephrotropic; Cerebroprotective.

(A) were tested for their ability to treat gastric lesions in rats using Kitagawa et al, J. Pharmacol. Exp. Ther., 253:1133-1137 (1990), and Al-Ghamdi et al, J. Int. Med. Res., 19:2242 (1991). The results show that relative gastric lesion activity of (N-methyl-N-(3-(nitrooxy)propyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate (Ib) was 0.02 .

MECHANISM OF ACTION - Cyclooxygenase (COX) inhibitor.

USE - (A) are used to treat or reduce inflammation, pain or fever, gastrointestinal disorder (an inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, constipation, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia), facilitates wound healing (ulcer), treat or reverse gastrointestinal, renal and/or respiratory toxicity, treat an inflammatory disease (cardiovascular disorder, reperfusion injury to an ischemic organ, angiogenesis, arthritis, asthma, bronchitis, premature labor, tendinitis, bursitis, an autoimmune disease, an immunological disorder, a skin-related condition, neoplasia (is a brain cancer, a bone cancer, an epithelial cell-derived neoplasia (epithelial carcinoma), a basal cell carcinoma, an adenocarcinoma, a gastrointestinal cancer, a lip cancer, a mouth cancer, an esophageal cancer, a small bowel cancer, a stomach cancer, a colon cancer, a liver cancer, a bladder cancer, a pancreas cancer, an ovary cancer, a cervical cancer, a lung cancer, a breast cancer, a skin cancer, a squamous cell cancer, a basal cell cancer, a prostate cancer, a renal cell carcinoma, a cancerous tumor, a growth, a polyp, an Adenomatous polyp, a familial adenomatous polyposis or a fibrosis resulting from radiation therapy), an inflammatory process in a disease, pulmonary inflammation, a central nervous system disorder (cortical dementia, Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile dementia, alcoholic dementia, senile dementia, memory loss or central nervous system damage resulting from stroke, ischemia or trauma)), allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, a microbial infection, a bacterial-induced inflammation, a viral induced inflammation, a urinary disorder, a urological disorder, endothelial dysfunction, organ deterioration, tissue deterioration, a sexual dysfunction or activation, adhesion and infiltration of neutrophils at the site of inflammation and to treat an ophthalmic disorder. (all claimed).

ADVANTAGE - (I) have good bioavailability, possess potent analgesic and antiinflammatory properties and have unexpected properties for reducing the formation of gastrointestinal lesions (ulcers).

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B05-B01E; B05-B01F; B06-H; B07-H; B10-A03; B10-A05; B10-A13D; B10-A17; B10-B01B; B10-B02J; B14-A01; B14-C01; B14-C03; B14-C04; B14-C09; B14-E01; B14-E08; B14-E09; B14-E10; B14-F01; B14-F02; B14-F05; B14-G02; B14-H01; B14-J01; B14-K01; B14-N03; B14-N04; B14-N07; B14-N10; B14-N17; B14-P03; B14-S06

=> b home

FILE 'HOME' ENTERED AT 07:13:56 ON 18 NOV 2004

Search done by Noble Jarrell

=>